Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Phase 1 Recruiting 100 enrolled Newave Pharmaceutical Inc

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

Timeline

Start: 2022-05-08
Primary completion: 2026-12-31
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LP-118	Small molecule	50 mg	Oral
Subject	LP-118	Small molecule	100 mg	Oral
Subject	LP-118	Small molecule	200 mg	Oral
Subject	LP-118	Small molecule	300 mg	Oral
Subject	LP-118	Small molecule	400 mg	Oral
Subject	LP-118	Small molecule	500 mg	Oral
Subject	LP-118	Small molecule	600 mg	Oral
Subject	LP-118	Small molecule	800 mg	Oral

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Summary

Timeline

Drugs

Indications